biotech · Hematological or solid tumor malignancies or autoimmune diseases · Intracerebral Haemorrhage · IPSC
Century Therapeutics
Century Therapeutics is a biotech organization headquartered in Philadelphia, USA. It trades on NYSE under ticker IPSC. Primary therapeutic focus areas include Hematological or solid tumor malignancies or autoimmune dise
Philadelphia, USA HQ
2018 Founded
104 Employees
Public company Type
IPSC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Philadelphia, USA
- Founded
- 2018
- Employees
- 104
- Programs
- 10
- Drugs
- 9
- Patents
- 39
CNTY-101
Phase 1 · mab · R/R CD19-Positive B-Cell Malignancies
CNTY-101 for R/R CD19-Positive B-Cell Malignancies is a Phase 1 program (mab) at Century Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CNTY-101-111-01 (ELiPSE-1)
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Century Therapeutics
- Phase
- Phase 1
- Modality
- mab
- Indication
- R/R CD19-Positive B-Cell Malignancies
- Status
- terminated
- Trials
- 1